檢索結果 - Chris Fourment

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study 由 Brian Bressler, Andrés Yarur, Mark S. Silverberg, Marielle Bassel, Emanuelle Bellaguarda, Chris Fourment, Anthie Gatopoulou, Pantelis Karatzas, Uri Kopylov, Giorgos D. Michalopoulos, Spyridon Michopoulos, Udayakumar Navaneethan, David T. Rubin, Jesse Siffledeen, Andrew Singh, Konstantinos Soufleris, Dara Stein, Dirk Demuth, Gerassimos J. Mantzaris